Cloudbreak Pharma (HKSE:02592) Long-Term Debt: HK$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02592 Cloudbreak Pharma Inc HKSE:02592
11 GF Score
Price HK$1.18
! 2 Warning Signs
View Full Analysis

What is Cloudbreak Pharma Long-Term Debt?

Cloudbreak Pharma HKSE:02592 +2.16% 11 Long-Term Debt is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Cloudbreak Pharma's Long-Term Debt for the quarter that ended in Dec. 2025 was HK$0.00 Mil.

Cloudbreak Pharma  (HKSE:02592) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cloudbreak Pharma Long-Term Debt Related Terms

Cloudbreak Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cloudbreak Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cloudbreak Pharma Long-Term Debt Chart

Cloudbreak Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00 0.00

Cloudbreak Pharma Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Long-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
HKSE:02592
11GF Score
Cloudbreak Pharma Inc HKSE:02592
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of HK$0.00 Mil mean?
Cloudbreak Pharma (HKSE:02592) has a Long-Term Debt of HK$0.00 Mil as of Dec. 2025.
Is Cloudbreak Pharma's Long-Term Debt too high?
Cloudbreak Pharma's current Long-Term Debt is HK$0.00 Mil. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Long-Term Debt compare to VRTX and REGN?
Cloudbreak Pharma's Long-Term Debt of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cloudbreak Pharma's current Long-Term Debt is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Long-Term Debt of HK$0.00 Mil. The current Long-Term Debt is HK$0.00 Mil. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Long-Term Debt is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cloudbreak Pharma Business Description

Address 8921 Research Drive, Irvine, CA, USA, 92618
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score

Get the complete analysis for HKSE:02592

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.18
Price